Ildong Pharmaceutical Co., Ltd. (249420.KS)
KRW 11350.0
(-5.42%)
KRW 11350.0
(-5.42%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 207.53 Billion KRW | -12.19% |
| 2022 | 236.34 Billion KRW | 7.7% |
| 2021 | 219.43 Billion KRW | -7.96% |
| 2020 | 238.41 Billion KRW | 2.61% |
| 2019 | 232.35 Billion KRW | -8.94% |
| 2018 | 255.15 Billion KRW | 12.79% |
| 2017 | 226.23 Billion KRW | 132.52% |
| 2016 | 97.29 Billion KRW | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | 56.68 Billion KRW | -0.78% |
| 2024 Q3 | 155.94 Billion KRW | 0.55% |
| 2024 Q1 | 57.13 Billion KRW | 8.02% |
| 2023 Q2 | 55.68 Billion KRW | 2.91% |
| 2023 Q3 | 49.82 Billion KRW | -10.51% |
| 2023 Q4 | 52.88 Billion KRW | 6.14% |
| 2023 FY | 207.53 Billion KRW | -12.19% |
| 2023 Q1 | 54.1 Billion KRW | -1.82% |
| 2022 Q4 | 55.1 Billion KRW | -9.37% |
| 2022 Q3 | 60.8 Billion KRW | -0.21% |
| 2022 Q2 | 60.93 Billion KRW | 2.39% |
| 2022 Q1 | 59.5 Billion KRW | 13.61% |
| 2022 FY | 236.34 Billion KRW | 7.7% |
| 2021 Q4 | 52.37 Billion KRW | -9.16% |
| 2021 Q2 | 58.19 Billion KRW | 13.66% |
| 2021 Q3 | 57.65 Billion KRW | -0.93% |
| 2021 FY | 219.43 Billion KRW | -7.96% |
| 2021 Q1 | 51.2 Billion KRW | -11.04% |
| 2020 FY | 238.41 Billion KRW | 2.61% |
| 2020 Q4 | 57.56 Billion KRW | -6.44% |
| 2020 Q3 | 61.52 Billion KRW | -6.8% |
| 2020 Q1 | 53.31 Billion KRW | 31.59% |
| 2020 Q2 | 66.01 Billion KRW | 23.83% |
| 2019 FY | 232.35 Billion KRW | -8.94% |
| 2019 Q2 | 67.89 Billion KRW | 7.12% |
| 2019 Q3 | 60.56 Billion KRW | -10.8% |
| 2019 Q4 | 40.51 Billion KRW | -33.11% |
| 2019 Q1 | 63.38 Billion KRW | -4.69% |
| 2018 Q4 | 66.5 Billion KRW | 2.47% |
| 2018 Q1 | 60.01 Billion KRW | 7.68% |
| 2018 Q2 | 63.73 Billion KRW | 6.19% |
| 2018 FY | 255.15 Billion KRW | 12.79% |
| 2018 Q3 | 64.9 Billion KRW | 1.84% |
| 2017 Q3 | 63.7 Billion KRW | 13.01% |
| 2017 Q2 | 56.36 Billion KRW | 11.77% |
| 2017 FY | 226.23 Billion KRW | 132.52% |
| 2017 Q4 | 55.73 Billion KRW | -12.51% |
| 2017 Q1 | 50.43 Billion KRW | -14.32% |
| 2016 Q4 | 58.86 Billion KRW | 53.14% |
| 2016 FY | 97.29 Billion KRW | 0.0% |
| 2016 Q3 | 38.43 Billion KRW | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 46.5 Billion KRW | -346.272% |
| Dong-A Socio Holdings Co., Ltd. | 364.1 Billion KRW | 43.001% |
| Ildong Holdings Co., Ltd. | 198.88 Billion KRW | -4.35% |
| HANDOK Inc. | 151.36 Billion KRW | -37.11% |
| Kukje Pharma Co., Ltd. | 67.22 Billion KRW | -208.725% |
| Yuhan Corporation | 564.5 Billion KRW | 63.235% |
| Dong-A ST Co., Ltd. | 322.21 Billion KRW | 35.589% |
| SAMSUNG PHARM. Co., LTD. | 23.74 Billion KRW | -773.956% |
| Hanmi Pharm. Co., Ltd. | 835.85 Billion KRW | 75.17% |
| Hanall Biopharma Co.,Ltd | 75.03 Billion KRW | -176.573% |
| Ilyang Pharmaceutical Co.,Ltd | 198.96 Billion KRW | -4.311% |
| Dong Sung Bio Pharm.Co.,Ltd. | 40.64 Billion KRW | -410.556% |
| MYUNGMOON Pharm co.,Ltd | 94.51 Billion KRW | -119.582% |
| Hana Pharm Co., Ltd. | 140.85 Billion KRW | -47.341% |
| Yuyu Pharma, Inc. | 46.5 Billion KRW | -346.272% |
| Ilsung Pharmaceuticals Co., Ltd. | 34.71 Billion KRW | -497.823% |
| REYON Pharmaceutical Co., Ltd. | 76.81 Billion KRW | -170.168% |
| Aprogen pharmaceuticals,Inc. | -12.04 Billion KRW | 1822.941% |
| JW Holdings Corporation | 446.15 Billion KRW | 53.483% |
| Chong Kun Dang Pharmaceutical Corp. | 655.34 Billion KRW | 68.331% |
| JW Pharmaceutical Corporation | 335.67 Billion KRW | 38.172% |
| Shin Poong Pharm.Co.,Ltd. | 78.61 Billion KRW | -163.978% |
| Hyundai Pharmaceutical Co., Ltd. | 75.23 Billion KRW | -175.843% |
| Samil Pharmaceutical Co.,Ltd | 72.21 Billion KRW | -187.404% |
| Jeil Pharmaceutical Co.,Ltd | 183.81 Billion KRW | -12.907% |
| Yuyu Pharma, Inc. | 46.5 Billion KRW | -346.272% |
| Kwang Dong Pharmaceutical Co., Ltd. | 295.11 Billion KRW | 29.676% |
| Daewoong pharmaceutical Co.,Ltd | 681.55 Billion KRW | 69.549% |
| JW Pharmaceutical Corporation | 335.67 Billion KRW | 38.172% |
| Yuhan Corporation | 564.5 Billion KRW | 63.235% |
| Jeil Pharma Holdings Inc | 201.82 Billion KRW | -2.833% |
| Yungjin Pharm. Co., Ltd. | 70.93 Billion KRW | -192.559% |
| Suheung Co., Ltd. | 99.02 Billion KRW | -109.578% |
| JW Pharmaceutical Corporation | 335.67 Billion KRW | 38.172% |
| Samjin Pharmaceuticals Co., Ltd. | 145.89 Billion KRW | -42.256% |
| Korea United Pharm Inc. | 173.48 Billion KRW | -19.627% |
| CKD Bio Corp. | 5.01 Billion KRW | -4042.242% |
| Daewon Pharmaceutical Co., Ltd. | 254.23 Billion KRW | 18.366% |
| Dongwha Pharm.Co.,Ltd | 184.12 Billion KRW | -12.717% |
| Whan In Pharm Co.,Ltd. | 98.12 Billion KRW | -111.504% |
| Shin Poong Pharm.Co.,Ltd. | 78.61 Billion KRW | -163.978% |
| Chong Kun Dang Holdings Corp. | 371.49 Billion KRW | 44.135% |
| Boryung Corporation | 333.26 Billion KRW | 37.726% |
| Bukwang Pharmaceutical Co., Ltd. | 50.04 Billion KRW | -314.7% |
| Ilyang Pharmaceutical Co.,Ltd | 198.96 Billion KRW | -4.311% |
| JW Lifescience Corporation | 51.32 Billion KRW | -304.362% |